The law firm of Federman & Sherwood has been retained by a shareholder of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) (“Sarepta” or “the Company”) to investigate Sarepta for possible violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and/or breaches of fiduciary duty by the Company’s officers and directors.
During its Q3 Earnings Conference Call on November 12, 2013, Sarepta announced that the Food and Drug Administration (“FDA”) had just advised the Company not to file for accelerated approval of its drug eteplirsen, which is used to treat Duchenne muscular dystrophy, citing “considerable doubt…on the efficacy support of eteplirsen.” This delay could push the potential approval of eteplirsen back by more than 2 years. Once this announcement was made, Sarepta shares dropped more than 64%, a 52-week low.
Federman & Sherwood is investigating whether Sarepta issued materially false and/or misleading statements or failed to disclose material facts surrounding the approval of
eteplirsen. If you currently own common stock in Sarepta Therapeutics, Inc., have any information to assist in our investigation, or have questions or concerns regarding this notice or your rights or interests in this matter, please contact William B. Federman at
firstname.lastname@example.org. Federman & Sherwood has extensive nationwide experience in representing investors in securities, derivative and merger-related shareholder class actions, and has been appointed as lead counsel in multiple complex cases across the country.